Schlagwort: BSV
„Investoren in Life Sciences – Qualität zählt, Kapital ist da“
Die Ausgangslage ist ambivalent: weniger Deals, volatile Märkte, steigende Anforderungen. Und doch fließt wieder deutlich mehr Venture Capital in Europas Life Sciences – 6...
Surging expected growth of drug approvals over the next decade
In March 2024, we reported a gradual increase of new drug approvals over the past 30 years, combined with an increasing focus on cancer,...
Can biopharma’s drug-focused R&D strategy remain profitable?
Since the 1990s, there has been a shift in focus within pharmaceutical R&D. It resulted in placing greater emphasis on areas such as cancer,...